HK Stock Market Move | EDDING GENOR (06998) rose nearly 4% after announcing preclinical data for the four specific antibodies EDP001 at the AACR Annual Meeting in 2026.

EDDING GENOR (06998) rose nearly 4%, as of the time of writing, it was up 3.34% to HK$3.4, with a trading volume of HK$5.134 million. In terms of news, on April 22nd, according to EDDING GENOR's official WeChat account, the company announced that its independently developed highly innovative quad-specific T-cell connector EDP001 (CD3/CD19/CD19/BCMA) will be presenting preclinical research data at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Preclinical studies have shown that EDP001 has strong in vitro cell killing capabilities, significant in vivo tumor growth inhibition effects, and lower levels of cytokine secretion. These results suggest that EDP001 has promising clinical prospects in B-cell lymphoma and B-cell-related autoimmune diseases. EDP001 is a cutting-edge innovative product developed independently on EDDING GENOR's large molecule antibody drug development platform, targeting the potentially huge areas of autoimmunity and B-cell lymphoma. This research platform focuses on novel molecular forms such as bispecific/multispecific antibodies, TCE, ADC, and has the full chain ability from target discovery to drug-like evaluations.